Darktrace, a Cambridge, UK and San Francisco, CA-based enterprise cybersecurity software provider, raised $65m in equity funding.
The round was led by KKR, with participation from existing investor Summit Partners, and new investors TenEleven Ventures and SoftBank-affiliated SB ISAT Fund.
The company intends to use the funds to further accelerate the global roll-out of its Enterprise Immune System technology.
Founded in 2013 and led by Nicole Eagan, CEO, Darktrace provides an enterprise immune system technology that detects and responds to threats, powered by machine learning and mathematics developed by specialists from the University of Cambridge. Without using rules or signatures, Darktrace is capable of understanding the pattern of life of every device, user and network within an organization, and defends against evolving threats that bypass all other systems.
Some of the world’s largest corporations use the technology in sectors including energy and utilities, financial services, telecommunications, healthcare, manufacturing, retail and transportation.
Darktrace currently has 300 employees at global offices in New York, Auckland, London, Milan, Mumbai, Paris, Singapore, Sydney, Tokyo, Toronto and Washington D.C.